Mealey's PI/Product Liability - FDA Wants Study Data To Evaluate Heart Failure Risk Among Onglyza Users

SILVER SPRING, Md. - The Food and Drug Administration on Feb. 11 said it is reviewing clinical trial data from the manufacturers and distributors of Onglyza and Kombiglyze brand saxagliptin for a risk of heart failure.

Access this news story on®